# Avacta

### **Affimer<sup>®</sup> proteins: A novel therapeutic platform**

#### **David H Jones, Fiona McLaughlin** Avacta Therapeutics, London, United Kingdom

Formatting options

Multiple Affimer<sup>®</sup> molecules can be covalently linked into a single protein: characteristics can be retained

· Linking repeat units enables modification of avidity. When an Affimer<sup>®</sup> is included which binds albumin, PK

## Affimer


POS038

#### Introduction

- · Affimer® proteins are based on the human protease inhibitor, Stefin A
- Loops may be inserted in the positions shown: these have the potential to bind target proteins with high affinity and high specificity. Insertions eliminate normal biological activity.
- Stefin A was selected as a scaffold as it is sufficiently stable to constrain a broad range of inserted peptides, and flexible enough that folding is not affected by the inserted peptides.
- · Stefin A is highly stable, has no post-translational modifications and can be produced at high levels in E.coli or mammalian cells.
- Stefin A is 11kDa, increasing to around 14kDa when Affimer<sup>®</sup> loops are present. This compares to 150kDa for an IgG antibody, and provides potential benefits for tissue penetration and clearance from the body.
- Production of multiple Affimer<sup>®</sup> molecules linked in series provides opportunities to generate multi-specific proteins and to modify pharmacokinetic properties.

#### Generation of Affimer<sup>®</sup> libraries and selections

- · Libraries have been generated with all structural liabilities eliminated, no bias in amino acid distribution and with optimized sequences for efficient screening processes.
- A loop size frequently utilised is 9 amino acids. Libraries are available with 9 amino acid loops at either both loop 2 and loop 4, or at loop 2 only. Libraries have a sequence diversity of around 10<sup>10</sup>.
- · Libraries with longer loop sizes have also been generated. These may offer access to hidden or novel epitopes; Affimer<sup>®</sup> molecules may be able to bind epitopes inaccessible to larger biologics.




#### Selections


· Input library binds to immobilized antigen


- Non-binding phage are washed away; phage which remain bound are eluted and bacteria infected with these phage to amplify.
- Multiple rounds of selection are performed.
- Isolation of specific phage (in parallel to next generation sequencing of pools) results in identification of Affimer® molecules which bind to the target protein.




- Stefin A exhibits a high melting temperature (Tm); Affimer<sup>®</sup> molecules with binding loops also exhibit high Tm's.
- This provides advantages for subsequent processing steps including radiolabelling.








and productivity of the resulting protein remains high.




#### Affimer<sup>®</sup> molecules may be linked to cytokines or other biologically active proteins

 Activity of an Affimer<sup>®</sup> - cytokine fusion protein is demonstrated in a mixed lymphocyte reaction. T cell activity is observed in a dose dependent manner for both Fc- and Affimer® PK extended molecules.



#### Affimer<sup>®</sup> molecules exhibit low immunogenicity


- Affimer<sup>®</sup> molecules exhibit low immunogenicity in CD8+ depleted PBMC proliferation measured by CD4+EdU+ cells.
- Affimer<sup>®</sup> molecules have also been demonstrated to elicit lower levels of anti-drug antibody response than commercial antibodies to the same target.




For further information please visit www.avacta.com

#### Biodistribution and in vivo activity

- Affimer® molecules exhibit tumour localisation in mice similar to that seen for commercial antibodies. Affimer® molecules may also be engineered to have distinct clearance compared to antibodies which has potential benefit in certain clinical settings.
- · Affimer® molecules (both Fc-linked and with PK-extending engineering) have shown activity in multiple in vivo tumour growth inhibition studies.






#### Tumour microenvironment activated conjugates: TMACs

 TMAC can bring together the preCISION<sup>™</sup> and the Affimer<sup>®</sup> platforms with a targeting moiety as well as the FAP-cleavable linker and a biologically active warhead.


In vivo tumour growth inhibition of test

TMACs has been observed.



#### **Diverse opportunities: AffyXell and MSCs**

- Affimer<sup>®</sup> molecules antagonistic to CD40L may be expressed on the surface of mesenchymal stem cells with no change to MSC gene expression or other characteristics.
- These engineered MSCs have the potential to modulate activity of host B cells.
- These Affimer<sup>®</sup> -expressing MSCs have been shown to reduce GvHD in mice.



#### Conclusions

- Affimer<sup>®</sup> molecules with specific binding characteristics may be rapidly isolated from phage display libraries. These may be further modified as multi-specific proteins or other fusion proteins, and PK properties modified as required.
- · Affimer® molecules are based on a human scaffold, exhibit low immunogenicity and have demonstrated in vivo activity in different clinical indications.
- Affimer<sup>®</sup> molecules may be engineered to various final formats: TMAC provides one opportunity, while radiolabelled or ADC options are also feasible.

